Codexis continues strategic expansion with purchase of JFC
US-based biosciences company Codexis has acquired Juelich Fine Chemicals (JFC), a leading German supplier of biocatalysts for organic synthesis and chiral building blocks.
US-based biosciences company Codexis has acquired Juelich Fine Chemicals (JFC), a leading German supplier of biocatalysts for organic synthesis and chiral building blocks.
JFC will operate as an independent, wholly owned subsidiary of Codexis.
JFC offers a wide range of off-the-shelf speciality enzymes and chiral intermediates used in pharmaceutical development. It will act as an outlet for several of Codexis' proprietary enzymes, while Codexis will continue to focus on using its MolecularBreeding directed molecular evolution technology to provide proprietary, customized solutions directly to leading pharmaceutical companies worldwide.
'The acquisition of JFC is part of our strategic expansion into international markets - in particular, Europe,' said Dr Alan Shaw, president and ceo of Codexis. 'We believe it will accelerate adoption of Codexis' biocatalytic approach to pharmaceutical process research and manufacturing, an area historically dominated by synthetic organic chemistry.'